e-Drug3D

1534

M TAFLUPROST

INN
TAFLUPROST

(is an active metabolite)

cas 209860-88-8

CLASS

OPEN-ANGLE GLAUCOMA
OCULAR HYPERTENSION
PROSTAGLANDIN ANALOG
FP PROSTANOID RECEPTOR AGONIST

ROUTE (list)

ATC code

S01EE05

PK parameters

Tmax 0.16 HOUR
Cmax 0.0634 NANOMOLAR (ONE DROP 0.0015 PERCENT)
PPB 99 PERCENT

Target

TARGET FP PROSTANOID RECEPTOR

PDB
8IUM (CRYO-EM STRUCTURE OF THE TAFLUPROST ACID-BOUND HUMAN PTGFR-GQ COMPLEX)

Ligand code = S2F (link to the list of PDB complexes)

Download experimental 3D coordinates of S2F with added hydrogens

DrugCentral

Prostaglandin F2-alpha receptor UNIPROT P43088 PTGFR

Download SDF file

5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-, (5Z)-

Formula:
C22H28F2O5

Calculated chemical properties:

MW 409.44
NB_atoms 29
XLogP 2.48
PSA 86.717
NB_HD 2
NB_HA 5
fsp3 0.50
Lipinski(0=no;1=yes) 1

FDA
-

Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL

e-Drug3D

1529

TAFLUPROST

INN
TAFLUPROST

(has an active metabolite)

cas 209860-87-7

CLASS

SENSORY
OPEN-ANGLE GLAUCOMA
OCULAR HYPERTENSION
PROSTAGLANDIN ANALOG
FP PROSTANOID RECEPTOR AGONIST

ROUTE (list)

OPHTHALMIC

ATC code

S01EE05

PK parameters

Solubility

PRACTICALLY INSOLUBLE IN WATER

Target

TARGET FP PROSTANOID RECEPTOR

DrugCentral

Prostaglandin F2-alpha receptor UNIPROT P43088 PTGFR

Download SDF file

1-methylethyl (5Z)-7-{(1R, 2R, 3R, 5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-butenyl}-3,5-dihydroxycyclopentyl]5-heptenoate

Formula:
C25H34F2O5

Calculated chemical properties:

MW 452.52
NB_atoms 32
XLogP 4.68
PSA 75.092
NB_HD 2
NB_HA 5
fsp3 0.56
Lipinski(0=no;1=yes) 1

FDA
NDA 202514 (label) INN (TAFLUPROST) ZIOPTAN (THEA PHARMA) APPROVAL= AP YEAR= 2012
NDA 209051 (pdf not found) INN (TAFLUPROST) TAFLUPROST (MICRO LABS) APPROVAL= AP YEAR= 2019
NDA 209040 (pdf not found) INN (TAFLUPROST) TAFLUPROST (SANDOZ) APPROVAL= AP YEAR= 2022
NDA 218002 (pdf not found) INN (TAFLUPROST) TAFLUPROST (INGENUS PHARMS LLC) APPROVAL= AP YEAR= 2024